消息人士：美國數字媒體公司Puck正與紅鳥資本洽談一筆投資交易，Puck估值約爲2.5億美元。

加沙和平委員會高級代表尼古拉·姆拉德諾夫：關於加沙的路線圖執行仍有重要問題懸而未決。

The FDA has approved Revolution Medicines' pancreatic cancer drug Daraxonrasib, which will be marketed as Rasonque. The drug is the first therapy targeting one of the disease's key molecular pathogenic mechanisms. A late-stage trial published in May showed Daraxonrasib nearly doubled typical survival in an aggressive form of pancreatic cancer to 13.2 months versus 6.7 months with chemotherapy, the current standard of care.